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Wepresent the case of a patientwith progressive Langerhans cell sarcomawhose cutaneous
lesions and nodal masses were treated with palliative radiotherapy. Response to relatively
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low doses of radiotherapy was both good and sustained. We recommend a dose of 15–30Gy
depending on treatment intention and volume of the lesions.
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We decided to treat the supraclavicular mass and the chestadiotherapy
. Case report
e present the case of a 63-year-old immunosuppressed
atient diagnosed with Langerhans cell sarcoma in 2004. Rel-
vant prior medical history includes a liver transplantation,
or which the patient received immunosuppressive therapy.
his current case report is a follow-up to a previously pub-
ished report which described in detail the patient’s indolent
utaneous lesions andnodal involvement.1 From2004 through
007, the patient underwent multiple lymphadenectomies
nd surgical interventions to resect the skin nodules and
iseased nodes. Histological analysis of various samples col-
ected during this period conﬁrmed the same diagnosis.
In 2007, the patient suffered a relapse, with disease pro-
ression evident at several nodal sites. As a result, weekly
inblastine chemotherapy was prescribed. Despite a partial
esponse, the disease began to advance again 5 months after
reatment. Chemotherapy was restarted, this time with a new
egimen (CHOP scheme for 6 cycles). Despite a positive initial
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oi:10.1016/j.rpor.2010.05.001response, progression occurred again, this time after only 3
months after chemotherapy had been completed. Given the
increasingly poor response to chemotherapy, the patient was
referred to our radiation oncology department for possible pal-
liative irradiation.
A physical examination showed bulky nodal masses
located in the left supraclavicular area and bilateral inguinal
region, and cutaneous lesions in the left thoracic wall (Images
1–4). The patient presented multiple skin lesions with small
subcutaneous nodules; the larger nodules were exophytic and
ulcerated. Additionally, he also complainedof pain in the supr-
aclavicular area.
A search of the literature revealed no previous reports on
the use of radiotherapy in this type of tumour. The patient
had been informed of this fact, but nevertheless agreed to pro-
ceed with treatment in the hope of alleviating his symptoms.wall to relieve the pain and shrink the uncomfortable ulcer-
ated cutaneous lesions. Radiotherapy was given over the left
supraclavicular mass with 6MV X-rays, 2 oblique AP-PA ﬁelds
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved
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Pictures 1–4 – Chest wall cutaneous lesions (1) and PET scan from supraclavicular (2) and inguinal (3 and 4) nodal masses
before radiotherapy.of a Linear Accelerator Clinac 2100 (VARIAN). The left chest
wall was treated with a 6MeV direct electron ﬁeld. In both
cases, treatment was administered with a normofractionated
scheme of 2Gy per fraction, 5 days per week.
During the second week of treatment, it became evident
that the lesions were responding well to treatment, with a
response that continued to improve over the following days.
After 36Gy of radiotherapy had been delivered, the response
of the mass and skin lesions was nearly complete. As a result,
we decided that no further radiation was necessary and treat-
ment was terminated. Tolerance was good, with the only
side-effects being mild esophagitis and grade 2 dermatitis.
During the course of irradiation treatment, the patient
complainedof pain in the area of the bilateral inguinalmasses.
Given the good response achieved in the other locations, we
decided to treat these areas as well. Two AP-PA ﬁelds of 18MV
X-rays were delivered over each site. The same dose was
Pictures 5–8 – Chest wall cutaneous lesions (5) and PET scan from
after radiotherapy.administered and at the end of treatment the response was
also nearly complete. Side-effects included grade 2 dermati-
tis, grade 1 asthenia, and grade 1 anemia (shown on blood
counts).
One month postradiotherapy, new cutaneous lesions
appeared outside of the treatment ﬁeld. A PET scan showed
disease progression at several nodal sites and in the lung,
pleura, and soft tissues. The patient was treated again
with chemotherapy (cyclophosphamide, 50mg/day and sub-
cutaneous methotrexate, 43mg), but he developed severe
neutropenia and died of septic shock, 6 months after the ﬁrst
radiotherapy treatment (February 2009). At the time of death
(August 2009), the irradiated areas of the skin continued to
maintain the good response achieved by radiotherapy and,
moreover, a PET scan showeda reduction inuptake in the supr-
aclavicular area and absence of metabolic activity at inguinal
regions (Images 5–8).
supraclavicular (6) and inguinal (7 and 8) nodal masses
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. Discussion
angerhans cell sarcoma (LCS) is a raremalignant proliferation
f Langerhans cells. LCS was ﬁrst deﬁned by the International
ymphoma Study Group in 2002.2 Prior to that time, multiple
erms were used to describe this entity, resulting in confu-
ion. Since 2002, only a few cases have been described in
he medical literature. Although those reports contain useful
nformation about thehistological features and clinical behav-
or of this neoplasm, information about treatment options is
uite limited, as is often the case with rare diseases.
Histologically, cellular atypia and mitoses are needed to
ifferentiate this disease from other Langerhans cell prolif-
rations. Diagnosis also requires CD1a positivity and/or the
resence of Birbeck granules.3 Lee et al.4 reviewed previous
eports in 2006 and found only 19 cases described in English-
anguage literature. Since that time, 6 new cases have been
eported1,5–10 (one of which was our patient, reported in 2007).
nterestingly, a second case of a LCS patient with a trans-
lanted liver was published in 2008.7
It appears that LCS occurs in a wide age range, though
ainly in the third and fourth decades of life. Although the
ost commonly affected organs are the lymph nodes and
kin, multiorgan involvement – which occurred in the case
e present here – is also known to be characteristic. The lung,
one marrow, and spleen are the organs most often involved.
From published reports, we knew that LCS had an aggres-
ive behavior in most cases. Unfortunately, information about
he effectiveness of treatments is lacking. Surgery seems to be
good option for isolated lesions or conﬁned nodal disease,
ut the beneﬁt of adjuvant treatment is unknown. Chemother-
py has been used for the treatment of metastatic disease.
lassical hematological schemes, such as CHOP and ESHAP,
ave been administered,7 and other drug combinations with
driamycin plus Ifosfamide, such as MAID (mesna, doxoru-
icin, ifosfamide, dacarbazine) have also been tested.9,11,12
evertheless, the best option for systemic treatment of LCS
as not yet been established.
Although we found no reports in the literature regard-
ng the response of LCS to radiotherapy, we do know that
angerhans cell histiocytosis, the benign counterpart of LCS,
esponds well to low-dose radiotherapy. For this reason, we
hought that radiotherapy might be useful as a local treat-
ent, at least for pain relief and symptom control.
In the case we present here, the lesions began shrink-
ng when the total dose reached 12–14Gy, and response was
lmost complete when the total dose passed 30Gy. At 36Gy,
complete response was achieved and maintained for a long
eriod. While lower doses may have been sufﬁcient, we were
ncouraged to continue irradiating based on the low toxicity
nd good response to increasing doses.As a result of our experience, we recommend this dose
ange in the treatment of these types of tumours, depending
n treatment intention, the presence or not of gross tumour
olume and its size.therapy 1 5 ( 2 0 1 0 ) 107–109 109
3. Conclusions
LCS responds well to radiotherapy and we believe irradiation
is a good option in selected cases with symptomatic or bulky
lesions. Based on our experience, we suggest a dose range of
15–30Gy, depending on the treatment intention and the vol-
ume of the lesions.
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